175.91
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Moderna Inc | MRNA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 175.91 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 175.91 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 115.03 - 336.3599 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 175.91 | USD |
Period:
Draw Mode:
Moderna Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 67.58B | 384.18M | 283.08M | $ 17.74B | $ 9.99B | 56.58 | 3.20 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | -1.05M | 5.80% |
Moderna News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRNA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 175.01 | 184.21 | 169.06 | 175.11 | 2,881,425 | 0.90 | 0.51% |
| 1 Month | 138.76 | 188.65 | 135.09 | 170.86 | 4,209,806 | 37.15 | 26.77% |
| 3 Months | 136.70 | 188.65 | 115.03 | 143.35 | 4,776,682 | 39.21 | 28.68% |
| 6 Months | 146.09 | 197.44 | 115.03 | 148.26 | 4,858,788 | 29.82 | 20.41% |
| 1 Year | 329.75 | 336.3599 | 115.03 | 173.55 | 6,526,518 | -153.84 | -46.65% |
| 3 Years | 20.30 | 497.17 | 17.68 | 154.80 | 12,376,534 | 155.61 | 766.55% |
| 5 Years | 22.00 | 497.17 | 11.54 | 149.45 | 9,741,550 | 153.91 | 699.59% |
Moderna Description
| Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases. |